Last reviewed · How we verify
Hiberix™ Vaccine
Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier.
Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier. Used for Prevention of invasive Haemophilus influenzae type b disease in infants and children.
At a glance
| Generic name | Hiberix™ Vaccine |
|---|---|
| Sponsor | LG Life Sciences |
| Drug class | Conjugate vaccine |
| Target | Haemophilus influenzae type b polysaccharide capsule (PRP) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified polyribosylribitol phosphate (PRP) polysaccharide from the Hib capsule conjugated to tetanus toxoid protein. This conjugation enhances immunogenicity by converting a T-cell-independent antigen into a T-cell-dependent response, resulting in stronger and more durable antibody production and immunological memory against Hib infection.
Approved indications
- Prevention of invasive Haemophilus influenzae type b disease in infants and children
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
Key clinical trials
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PHASE3)
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) (PHASE3)
- Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
- Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (PHASE4)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hiberix™ Vaccine CI brief — competitive landscape report
- Hiberix™ Vaccine updates RSS · CI watch RSS
- LG Life Sciences portfolio CI